Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z5SM
|
|||
| Former ID |
DAP001276
|
|||
| Drug Name |
Sodium Tetradecyl Sulfate
|
|||
| Synonyms |
STDS; Trombavar; Monotetradecylsulfate sodium salt; Natri tetradecylsulfas; Natrii tetradecyclis sulfas; Sodium myristyl sulfate; Sodium tetradecyl sulphate; Sodium tetradecylsulfate; Sotradecol Sodium; Tetradecyl sodium sulfate; Niaproof 4; Tesapon K 14; Texapon K 14; Myristyl sulfate, sodium salt; Natrii tetradecyclis sulfas [INN-Latin]; Tetradecilsulfato sodico [INN-Spanish]; Tetradecyl sulfate de sodium [INN-French]; Tetradecyl sulfate, sodium salt; Fibro-Vein (TN); S.T.D; Sulfuric acid, monotetradecyl ester, sodium salt; Sulfuric acid, myristyl ester, sodium salt; S.T.D.; 1-Tetradecanol, 1-(hydrogen sulfate), sodium salt (1:1); 1-Tetradecanol, hydrogen sulfate, sodium salt
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hemangioma [ICD-11: 2E81-2F2Y] | Approved | [1], [2] | |
| Varicose and spider veins of leg [ICD-11: BD74.1; ICD-10: I83, I83.9] | Approved | [1], [2] | ||
| Therapeutic Class |
Sclerosing Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H29NaO4S
|
|||
| Canonical SMILES |
CCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
|
|||
| InChI |
1S/C14H30O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17;/h2-14H2,1H3,(H,15,16,17);/q;+1/p-1
|
|||
| InChIKey |
UPUIQOIQVMNQAP-UHFFFAOYSA-M
|
|||
| CAS Number |
CAS 1191-50-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D01509 ; BADD_D02050 ; BADD_D02182 | |||
| SuperDrug ATC ID |
C05BB04
|
|||
| SuperDrug CAS ID |
cas=001191500
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vitamin K-dependent protein C (PROC) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Beta2 integrin cell surface interactions | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Common Pathway of Fibrin Clot Formation | ||||
| Gamma-carboxylation of protein precursors | ||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | ||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | ||||
| Cell surface interactions at the vascular wall | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040541. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.